Atrion (NASDAQ:ATRI) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Atrion (NASDAQ:ATRI) in a research report sent to investors on Monday. The brokerage issued a sell rating on the medical instruments supplier’s stock.

Atrion Stock Performance

Shares of ATRI opened at $454.47 on Monday. Atrion has a 1 year low of $274.98 and a 1 year high of $593.00. The stock has a market capitalization of $799.87 million, a PE ratio of 42.71 and a beta of 0.68. The stock has a 50-day simple moving average of $449.56 and a 200-day simple moving average of $405.09.

Atrion (NASDAQ:ATRI) last issued its earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The firm had revenue of $47.33 million for the quarter.

Atrion Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 28th. Investors of record on Friday, June 14th were issued a $2.20 dividend. This represents a $8.80 annualized dividend and a yield of 1.94%. The ex-dividend date of this dividend was Friday, June 14th. Atrion’s dividend payout ratio (DPR) is presently 82.71%.

Institutional Trading of Atrion

A number of institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its position in shares of Atrion by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,385 shares of the medical instruments supplier’s stock worth $4,291,000 after acquiring an additional 243 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Atrion during the 4th quarter worth approximately $108,000. First Financial Corp IN purchased a new stake in shares of Atrion during the 4th quarter worth approximately $136,000. Copeland Capital Management LLC boosted its holdings in shares of Atrion by 56.4% in the 4th quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 31 shares in the last quarter. Finally, Boston Trust Walden Corp grew its position in shares of Atrion by 4.8% in the 4th quarter. Boston Trust Walden Corp now owns 35,091 shares of the medical instruments supplier’s stock valued at $13,292,000 after buying an additional 1,609 shares during the last quarter. 66.19% of the stock is owned by hedge funds and other institutional investors.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.